

NOV. 19. 2003 12:39PM

858 792-6773 FOLEY AND LARDNER

NO. 5865 P. 1

138

FOLEY & LARDNER

ATTORNEYS AT LAW

11250 EL CAMINO REAL, SUITE 200
SAN DIEGO, CA 92130
P.O. BOX 80278
SAN DIEGO, CALIFORNIA 92138-0278
TELEPHONE: 858.847.6700
FACSIMILE: 858.792.6773
WWW.FOLEY.COM

FACSIMILE TRANSMISSION

Total # of Pages 2 (including this page)

TO:	PHONE #:	FAX #:
Examiner R. Mitra US PTO Art Unit 1653	703 605-1211	703 746-5334

From : Wesley B. Ames
Email Address : wames@foley.com
Sender's Direct Dial : 858.847.6714
Date : November 19, 2003 12:37 PM
Client/Matter No : 073406-0403
User ID No : 0188

MESSAGE:

Application # 09/454252

If there are any problems with this transmission or if you have not received all of the pages, please call 858.847.6700.

Operator:	Time Sent:	Return Original To: Wesley B. Ames
-----------	------------	---------------------------------------

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

xxx:xxxxxx.xa

Cover Page 1 of 1

FOLEY & LARDNER

November 19, 2003

Examiner Mitra:

As you just requested in our telephone conversation, we are requesting a telephonic interview to discuss the Section 102 rejection of the claims over Jaynes, WO 89/00199. We do not find any anticipating description in this reference, as it does not describe any "target identification", nor any description of phage polypeptide binding to bacterial protein. We believe that it merely describes certain phage proteins that exhibit antibacterial activity.

In view of this, we would like to discuss the reference and the rejections, including the specific basis for the outstanding rejections. We believe that this discussion will facilitate more efficient prosecution by allowing us to directly address the issues. Thank you.

Wesley B. Ames